Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Raleigh-Cary, NC MSA — October 2026
Raleigh biopharma build-out collides with a thin specialist bench.
Raleigh-Cary unemployment sits at 3.1% while Clinical Research Associate pay hits $114,419 — 27% above the national median — as Amgen and J&J's combined $3B in regional manufacturing investment competes for the same scarce CMC and quality talent pool.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Raleigh-Cary unemployment rate: 3.1% — vs 4.2% national, down 0.5pt YoY
- Metro CRA advertised pay: $114,419 — vs $90,065 national median
- NC life sciences capital investment since 2022: $19B — 91 projects, 10,000+ jobs statewide
- National lab/R&D vacancy rate: 23.2% — Top 13 U.S. life sciences markets, Q1 2026
Key takeaways
Raleigh's CRA pay premium outpaces the national market by 27%.
Metro median advertised pay for Clinical Research Associates sits at $114,419 against a $90,065 national figure, a gap wide enough to change the math on insourcing versus CRO reliance. Employers benchmarking against national CRA data risk underpricing the role for this metro specifically.
Lab Technician pay is falling even as the broader market tightens.
Metro median advertised pay for Lab Technicians dropped significantly to $44,245 while Raleigh unemployment sits at 3.1%, a divergence worth investigating closely. This may reflect a shift toward less-credentialed entry pathways NCBiotech has flagged for manufacturing backfill, alongside softening demand for the role itself.
Validation Engineer and Clinical Data Manager pay softness contradicts the hiring narrative.
Both roles show significant metro pay declines — Validation Engineer to $98,188 and Clinical Data Manager to $96,409 against a $123,653 national figure — even as national life sciences employers report active recruiting and vacancy rates near 23%. Compensation benchmarking should separate role-specific softness from the metro's overall tightness before adjusting offers downward.
Manufacturing capacity growth is quietly narrowing the outsourcing option.
Amgen and J&J's combined $3B in regional biologics and pharma manufacturing investment pulls specialized quality and CMC talent into incumbent employers, leaving less bench strength available to CDMOs and smaller biotechs. Build-vs-outsource decisions made a year ago may need revisiting given how concentrated local manufacturing talent has become.
Median advertised pay by role — Raleigh-Cary, NC MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $105,786 | $128,641 | $176,464 | Moderate increase | $130,339 |
| Clinical Research Associate | $80,080 | $114,419 | $122,508 | Significant increase | $90,065 |
| Lab Technician | $37,440 | $44,245 | $49,920 | Significant decline | $47,840 |
| Regulatory Affairs Specialist | $96,076 | $119,186 | $132,201 | Stable | $103,780 |
| Clinical Data Manager | $96,408 | $96,409 | $117,900 | Significant decline | $123,653 |
| Biostatistician | $126,729 | $142,332 | $150,645 | Moderate increase | $131,958 |
| Validation Engineer | $89,284 | $98,188 | $102,532 | Significant decline | $106,478 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Raleigh-Cary's unemployment rate held at 3.1% in August, tied for the lowest among NC metros, as total nonfarm employment reached 787,200 — up 2.2% year-over-year — driven in part by continued life sciences capital investment including Amgen's $1B Holly Springs expansion and J&J's $2B Wilson County campus build-out. Statewide, NC has logged 91 life sciences projects since 2022 representing $19B in investment and 10,000-plus jobs, concentrating specialized hiring demand in a metro where the overall labor pool is already historically tight.
What it means
Manufacturing scale-ups by Amgen and J&J are absorbing quality, clinical, and CMC-adjacent talent faster than the regional pipeline can replace it, which raises the cost and risk of in-house build strategies for mid-size biopharma competing against deep-pocketed incumbents for the same credentialed workers. Metro advertised pay for Clinical Research Associates has climbed to $114,419 — well above the $90,065 national median — signaling that experienced clinical operations talent in Raleigh now commands a premium that may outpace what CRO partnerships can offset. Organizations should evaluate whether current CRA and CMC compensation structures reflect this local premium before assuming a CRO engagement is the lower-cost path.
Looking ahead
Expected: Amgen's Holly Springs expansion and J&J's Wilson County campus will continue hiring into 2027, and Raleigh employers should expect continued upward pressure on CMC, quality, and biomanufacturing compensation as these projects ramp staffing.
Worth watching: Lab Technician and Validation Engineer pay declines diverge from the metro's 3.1% unemployment rate; watch whether Q4 advertised pay data confirms a structural shift toward lower-credential entry hiring or reflects a temporary posting mix anomaly.
Emerging pressure point: National CRA vacancy pressure (23.2% lab/R&D vacancy across top markets) combined with Raleigh's above-national CRA pay suggests this role may see the sharpest compensation movement of any life sciences function locally over the next two quarters.
Potential inflection point: NC's 8,000-plus biopharma manufacturing worker need by 2026 intersects with slowing bottom-quartile wage growth statewide (3.5%, down from 7.5%); watch whether Raleigh employers widen entry-level pay to compete for the same shrinking pool drawing from Amgen and J&J pipelines.
Sources
- NC Department of Commerce / BLS — Raleigh-Cary unemployment at 3.1% in August 2026, among lowest in NC
- NC Biotech / state economic development reporting — Amgen Holly Springs $1B expansion creating 370 jobs
- NC Biotech / state economic development reporting — J&J $2B Wilson County pharmaceutical manufacturing campus, 420 jobs
- Industry labor market research — Lab/R&D vacancy reached 23.2% across top 13 U.S. life sciences markets Q1 2026
- NC Biotech — NC 91 life sciences projects since 2022 totaling $19B investment
- Industry labor market research — National biopharma quit rate at 1.9% limiting candidate availability
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.